Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
- Herrmann, R
- Bodoky, G
- Ruhstaller, T
- Glimelius, B
- Bajetta, E
- Schüller, J
- Saletti, P
- Bauer, J
- Figer, A
- Pestalozzi, B
- Köhne, CH
- Mingrone, W
- Stemmer, SM
- Tàmas, K
- Kornek, GV
- Koeberle, D
- Cina, S
- Bernhard, J
- Dietrich, D
- Scheithauer, W
- Swiss, Group for Clinical Cancer Research
- Central, European Cooperative Oncology Group
Publication date
January 2007
DOI Publisher
American Society of Clinical Oncology (ASCO) ISSN
0732-183XAbstract
This phase III trial compared the efficacy and safety of gemcitabine (Gem) plus capecitabine (GemCap) versus single-agent Gem in advanced/metastatic pancreatic cancer
Add to ORKG